Your browser is no longer supported. Please, upgrade your browser.
ENTX Entera Bio Ltd. monthly Stock Chart
Entera Bio Ltd.
Index- P/E- EPS (ttm)-0.84 Insider Own41.20% Shs Outstand18.23M Perf Week2.39%
Market Cap19.50M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float10.72M Perf Month-0.94%
Income-12.50M PEG- EPS next Q-0.15 Inst Own10.40% Short Float0.35% Perf Quarter-20.15%
Sales0.30M P/S64.98 EPS this Y1.20% Inst Trans-0.99% Short Ratio0.35 Perf Half Y-49.53%
Book/sh0.40 P/B2.68 EPS next Y- ROA-99.00% Target Price- Perf Year-55.60%
Cash/sh- P/C- EPS next 5Y- ROE-151.10% 52W Range1.00 - 3.40 Perf YTD-50.00%
Dividend- P/FCF- EPS past 5Y- ROI-93.90% 52W High-68.82% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin13.70% 52W Low6.00% ATR0.06
Employees21 Current Ratio2.60 Sales Q/Q0.00% Oper. Margin- RSI (14)41.52 Volatility6.34% 6.21%
OptionableNo Debt/Eq0.04 EPS Q/Q-50.40% Profit Margin- Rel Volume0.30 Prev Close1.07
ShortableYes LT Debt/Eq0.01 EarningsNov 19 BMO Payout- Avg Volume106.87K Price1.06
Recom2.00 SMA20-2.51% SMA50-7.43% SMA200-42.63% Volume22,585 Change-0.93%
Nov-19-20 06:45AM  
Nov-13-20 07:30AM  
Nov-09-20 08:30AM  
Nov-02-20 04:05PM  
Sep-10-20 08:30AM  
Aug-24-20 10:19AM  
Aug-20-20 08:00AM  
Aug-17-20 08:30AM  
Aug-10-20 08:30AM  
Aug-05-20 08:30AM  
Jul-23-20 08:25AM  
Jul-22-20 04:05PM  
Jul-07-20 08:30AM  
May-21-20 06:30AM  
May-17-20 12:30PM  
May-07-20 08:30AM  
Mar-26-20 06:30AM  
Mar-16-20 04:15PM  
Feb-04-20 07:30AM  
Dec-18-19 04:30PM  
Dec-11-19 05:00PM  
Nov-21-19 07:00AM  
Nov-18-19 08:37AM  
Nov-07-19 04:30PM  
Oct-07-19 08:00AM  
Sep-23-19 08:00AM  
Sep-19-19 11:36AM  
Aug-20-19 07:00AM  
Aug-15-19 07:00AM  
Aug-05-19 08:00AM  
Jul-11-19 12:23PM  
Jul-02-19 07:00AM  
Jul-01-19 08:00AM  
Jun-27-19 07:00AM  
Mar-28-19 07:00AM  
Mar-27-19 11:02AM  
Mar-07-19 07:00AM  
Jan-31-19 08:00AM  
Jan-22-19 08:00AM  
Jan-10-19 07:00AM  
Dec-11-18 09:32AM  
Nov-08-18 08:00AM  
Oct-02-18 08:00AM  
Sep-21-18 09:15AM  
Aug-20-18 04:05PM  
Aug-09-18 12:00PM  
Aug-01-18 08:00AM  
Jul-02-18 04:05PM  
Jun-28-18 08:53AM  
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.